VRDN

Viridian Therapeutics, Inc./DE

VRDN · CIK 1590750 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20182025
Net Income−$343M
20182025
Operating CF−$276M
20182025
Free Cash Flow−$277M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue————————
Cost of Revenue————————
Gross Profit————————
R&D Expense——————$0.0B$0.0B
SG&A Expense$0.1B———————
Operating Income$-0.4B$-0.3B$-0.3B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
Net Income$-0.3B$-0.3B$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
EPS (Basic)——$-5.31$-4.05$-6.66———
EPS (Diluted)——$-5.31$-4.05$-6.66———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.9B$0.7B$0.5B$0.4B$0.2B$0.1B$0.0B$0.1B
Current Assets$0.9B$0.7B$0.5B$0.4B$0.2B$0.1B$0.0B$0.1B
Cash & Equivalents———————$0.0B
Total Liabilities$0.2B$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.7B$0.7B$0.4B$0.4B$0.2B$0.1B$0.0B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.3B$-0.2B$-0.2B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B$0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.4B$0.5B$0.2B$0.3B$0.1B$0.1B$0.0B$0.0B
← Companies